US drug regulator clears Qnovia’s nicotine inhaler for clinical testing
HQ Team October 7, 2024: The US Food and Drug Administration (FDA)has cleared Qnovia Inc’s nicotine inhaler RespiRx for clinical trial. The US
HQ Team October 7, 2024: The US Food and Drug Administration (FDA)has cleared Qnovia Inc’s nicotine inhaler RespiRx for clinical trial. The US
Extreme warming in the Antarctic Peninsula has increased the vegetation cover in the region by more than tenfold over the last four decades,
he Democratic Republic of the Congo has started mpox vaccination aiding efforts to halt the spread of the viral disease, according to the
Johnson & Johnson has discontinued its mid-stage trial, evaluating an antiviral drug, mosnodenvir, for the prevention of dengue.
Italy’s Recordati will acquire global rights for Sanofi’s drug Enjaymo, used in the treatment of a rare autoimmune disease that causes the body's
Novo Nordisk will invest 864 million reais ($158 million) to revamp its Brazil unit, which accounts for 25% of the drugmaker’s insulin shipments
The European Medicines Agency is reviewing two medicines meant to treat hair loss and prostate enlargement following concerns regarding suicidal ideation and behaviours.